W.K. Alfred Yung
MD
Professor
👥Biography 个人简介
Research on IDH-mutant lower-grade gliomas has advanced significantly with the INDIGO trial establishing vorasidenib (oral IDH1/2 inhibitor) for grade 2 IDH-mutant glioma — the first new treatment to improve progression-free survival in this disease in many years. IDH mutations occur in the majority of lower-grade gliomas and represent a key molecular target, with vorasidenib representing an important advance for this younger patient population.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 W.K. Alfred Yung 的研究动态
Follow W.K. Alfred Yung's research updates
留下邮箱，当我们发布与 W.K. Alfred Yung（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment